GlassScriptPhysician profile
Lloyd Cortez Alcera
NPI 1184854259
$186,889.61
in general payments reported to CMS, 2019-2025
22 companies · $58K in 2025
The $58K reported for 2025 was more than what 98% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36K · 2020: $10K · 2021: $14K · 2022: $35K · 2023: $12K · 2024: $22K · 2025: $58K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $82K · Travel and Lodging: $5,150 · Food and Beverage: $4,147 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $82,072.58 |
| Travel and Lodging | $5,150.47 |
| Food and Beverage | $4,147.00 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $152,817.03 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| E.R. Squibb & Sons, L.L.C. | $25,396.90 | 2024-2025 | Cobenfy |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $4,571.72 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $607.41 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $542.03 | 2019-2023 | Austedo Xr, Austedo |
| Sunovion Pharmaceuticals INC. | $465.69 | 2019-2022 | |
| Lundbeck LLC | $365.07 | 2019-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $330.57 | 2019-2022 | |
| Alkermes, INC. | $313.04 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $296.68 | 2021-2025 | Caplyta |
| Corium, LLC | $238.34 | 2022-2025 | Azstarys |
| Abbvie INC. | $233.36 | 2021-2023 | Vraylar |
| Takeda Pharmaceuticals U.S.A., INC. | $192.61 | 2019-2023 | Trintellix |
| Allergan, INC. | $176.67 | 2019 | |
| Ironshore Pharmaceuticals INC. | $66.76 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $59.35 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $59.13 | 2019 | |
| Idorsia Pharmaceuticals US INC | $58.51 | 2022-2023 | Quviviq |
| Shire North American Group INC | $42.58 | 2019 | |
| Vanda Pharmaceuticals INC. | $26.64 | 2019-2022 | |
| Neos Therapeutics, LP | $16.08 | 2023 | Adzenys Xr-Odt |
| Arbor Pharmaceuticals, INC. | $13.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lloyd Alcera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.